Crown Bioscience, a fully owned subsidiary of Crown Bioscience International, has entered a collaboration with Jiangsu Qyun Bio-Pharmaceutical to develop a CTLA-4 antibody.

Under the collaboration, CrownBio will utilise Jiangsu Qyun Bio-Pharmaceuticals' expertise to assist in the investigational new drug (IND) application and advance the development of its 10B10 antibody.

CrownBio CEO Jean-Pierre Wery said: “The collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical is indicative of our focus on innovation, and enhances our portfolio in immuno-oncology.

“Moreover, this partnership highlights CrownBio’s commitment to develop therapies that could significantly impact the way cancer is treated.”

The company claimed that 10B10 is a humanised anti-CTLA-4 antibody that has a higher binding affinity and in vitro T-cell stimulation than ipilimumab.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical is indicative of our focus on innovation, and enhances our portfolio in immuno-oncology."

Ipilimumab is the first immune checkpoint blockade antibody that targets CTLA-4 and has applied for FDA approval to treat melanoma.

Both antibodies exhibited equivalent activity in T-cell activation and tumour growth suppression but with a different binding epitope and pharmacokinetic profile.

Jiangsu Qyun Bio-Pharmaceuticals CEO Qiu Jiwan said: “CrownBio is the ideal partner to progress candidate compounds to IND and clinical development thanks to their recognised in vivo pharmacology expertise and the high quality and standards of their operations, representing the perfect match to our know-how in antibody engineering, cell line construction, and experience in GMP production management, quality control, clinical research, and regulatory affairs."

The collaboration is designed to develop a less toxic CTLA-4 antibody with better combination strategies able to overcome all the immunological adverse effects due to T-cell activation and proliferation found in some patients when treated with anti-CTLA-4 immunotherapies.

Image: Crystal structure of CTLA4. Photo: courtesy of RaminHerati via Wikipedia.